| Name | Title | Contact Details |
|---|---|---|
Shannon West |
Chief Innovation Officer | Profile |
Tim Hill |
Director of Technology Risks | Profile |
Daniel Sergile |
Deputy Chief Information Security Officer | Profile |
At Indi we believe that a systems-based approach is necessary to understand complex diseases and improve health. Our mission is to dramatically improve diagnosis and management of complex diseases by building advanced molecular diagnostics and creating new diagnostic technologies. We seek to understand the complex biological systems from which diseases arise so that we can determine which combinations of biomarkers have the greatest diagnostic power. Then we build assays capable of measuring hundreds of proteins at a time, for more precise detection and management of disease. Our end goal is to create large-scale systems medicine diagnostics that can gather a wealth of information – and then make sense of that information so that physicians can better diagnose disease.
General Systems Designs Inc is a Cedar Rapids, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Biodynamics Engineering is a Pacific Palisades, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.
GCG Communications is a Reston, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.